3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
7
Unknown
2
Terminated
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Overweight
1
Obesity
1
Neoplasms
1
Motor Activity
1
Metabolic Diseases
1
Hypertension
1
Hypercholesterolemia
1
Heart Diseases
1
Diabetes Mellitus, Type 2
1
Cardiovascular Diseases
1
Advanced Malignant Solid Neoplasm
1
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Nutrition Assessment
×
Clear all
NCT07126587
2025-10-30
HLA
University of North Carolina, Chapel Hill
Phase NA
Recruiting
120 enrolled